Abu Dhabi advances gene editing therapies targeting rare diseases through strategic global collaboration. WAM 25 Jun 2026, 14:13 GMT+ ABU DHABI, 25th June, 2026 (WAM) - The Department of Health - Abu Dhabi (DoH), M42 and Mammoth Biosciences have signed a Memorandum of Understanding at the BIO International Convention 2026 in San Diego to advance gene-editing therapies, develop clinical research and advance therapy manufacturing in Abu Dhabi. The partnership strengthens Abu Dhabi's established genomics and precision medicine ecosystem, marking an important step in the Emirate's progression from genomic sequencing to therapeutic development within a single integrated ecosystem. Leveraging insights generated through the Emirati Genome Programme (EGP), the collaboration will support the development of next -generation treatments for inherited diseases while expanding Abu Dhabi's capabilities across clinical research, advanced therapy manufacturing and scientific innovation. The collaboration also supports Abu Dhabi's broader efforts to strengthen its life sciences sector through the Health, Endurance, Longevity and Medicine (HELM) Cluster, which aims to accelerate the development of healthcare innovation across research, clinical development, manufacturing and commercialisation. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, said, "Abu Dhabi has built a strong foundation in genomics and precision medicine through long-term investments in research and innovation. The next step is translating these insights into therapies that can address some of the most complex diseases affecting communities in our region and around the world." As part of this strategic partnership, DoH will provide the regulatory framework and research environment, M42 will provide population genomics, healthcare and clinical research infrastructure and Mammoth Biosciences will bring a pioneering gene editing platform built on breakthrough CRISPR* science. Together, the partners aim to accelerate the journey from scientific discovery to population scale impact. Dr. Fahed Al Marzooqi, Chief Executive Officer, Integrated Health Solutions, M42, said, "The Emirati Genome Programme has generated insights that are helping us better understand the health needs of our population. Through this collaboration, we are creating opportunities to build on that foundation by supporting the development of advanced therapies while strengthening Abu Dhabi's research, clinical and manufacturing capabilities." Trevor Martin, Chief Executive Officer, Mammoth Biosciences, said, "What stands out about Abu Dhabi is its ability to bring together genomics, healthcare, clinical research and regulation within a single ecosystem. That creates a strong environment for advancing new therapeutic approaches and expanding access to cutting-edge innovation." The agreement spans four interconnected areas designed to accelerate the development and deployment of advanced therapy medicinal products (ATMPs). The parties will collaborate to introduce Mammoth's lead clinical candidate, MB-111, into Abu Dhabi's clinical research ecosystem, qualify local sites for advanced gene therapy and gene-editing trials, and support capability transfer to local clinical teams. The partnership will also support the establishment of advanced therapy manufacturing capabilities in Abu Dhabi, beginning with GMP lipid nanoparticle (LNP) production and advancing towards fully integrated GMP manufacturing. Additionally, the partnership will build long-term local expertise in CRISPR-based gene editing through structured training and workforce development programs. As Abu Dhabi continues to build capabilities across the healthcare value chain, from genomics and clinical research to advanced therapy development and manufacturing, the collaboration marks an important milestone in the Emirate's efforts to translate scientific insights into real-world treatments and expand its role in advancing precision medicine and life sciences innovation.

Abu Dhabi advances gene editing therapies targeting rare diseases through strategic global collaboration. WAM 25 Jun 2026, 14:13 GMT+ ABU DHABI, 25th June, 2026 (WAM) - The Department of Health - Abu Dhabi (DoH), M42 and Mammoth Biosciences have signed a Memorandum of Understanding at the BIO International Convention 2026 in San Diego to advance gene-editing therapies, develop clinical research and advance therapy manufacturing in Abu Dhabi. The partnership strengthens Abu Dhabi's established genomics and precision medicine ecosystem, marking an important step in the Emirate's progression from genomic sequencing to therapeutic development within a single integrated ecosystem. Leveraging insights generated through the Emirati Genome Programme (EGP), the collaboration will support the development of next -generation treatments for inherited diseases while expanding Abu Dhabi's capabilities across clinical research, advanced therapy manufacturing and scientific innovation. The collaboration also supports Abu Dhabi's broader efforts to strengthen its life sciences sector through the Health, Endurance, Longevity and Medicine (HELM) Cluster, which aims to accelerate the development of healthcare innovation across research, clinical development, manufacturing and commercialisation. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, said, "Abu Dhabi has built a strong foundation in genomics and precision medicine through long-term investments in research and innovation. The next step is translating these insights into therapies that can address some of the most complex diseases affecting communities in our region and around the world." As part of this strategic partnership, DoH will provide the regulatory framework and research environment, M42 will provide population genomics, healthcare and clinical research infrastructure and Mammoth Biosciences will bring a pioneering gene editing platform built on breakthrough CRISPR* science. Together, the partners aim to accelerate the journey from scientific discovery to population scale impact. Dr. Fahed Al Marzooqi, Chief Executive Officer, Integrated Health Solutions, M42, said, "The Emirati Genome Programme has generated insights that are helping us better understand the health needs of our population. Through this collaboration, we are creating opportunities to build on that foundation by supporting the development of advanced therapies while strengthening Abu Dhabi's research, clinical and manufacturing capabilities." Trevor Martin, Chief Executive Officer, Mammoth Biosciences, said, "What stands out about Abu Dhabi is its ability to bring together genomics, healthcare, clinical research and regulation within a single ecosystem. That creates a strong environment for advancing new therapeutic approaches and expanding access to cutting-edge innovation." The agreement spans four interconnected areas designed to accelerate the development and deployment of advanced therapy medicinal products (ATMPs). The parties will collaborate to introduce Mammoth's lead clinical candidate, MB-111, into Abu Dhabi's clinical research ecosystem, qualify local sites for advanced gene therapy and gene-editing trials, and support capability transfer to local clinical teams. The partnership will also support the establishment of advanced therapy manufacturing capabilities in Abu Dhabi, beginning with GMP lipid nanoparticle (LNP) production and advancing towards fully integrated GMP manufacturing. Additionally, the partnership will build long-term local expertise in CRISPR-based gene editing through structured training and workforce development programs. As Abu Dhabi continues to build capabilities across the healthcare value chain, from genomics and clinical research to advanced therapy development and manufacturing, the collaboration marks an important milestone in the Emirate's efforts to translate scientific insights into real-world treatments and expand its role in advancing precision medicine and life sciences innovation.

Abu Dhabi partners with a US biotechnology company to develop advanced gene-editing therapies. June 25, 2026 The new collaboration seeks to advance the development of treatments for rare and inherited diseases. Abu Dhabi has taken another significant step in advancing precision medicine after the Department of Health - Abu Dhabi (DoH), M42, and US-based Mammoth Biosciences signed a memorandum of understanding (MoU) to develop gene-editing therapies for rare and inherited diseases. The agreement was announced at the BIO International Convention 2026 in San Diego and is aimed at strengthening Abu Dhabi's growing life sciences sector by supporting clinical research, advanced therapy manufacturing, and scientific innovation. Officials said the collaboration builds on the emirate's ongoing investments in genomics and precision medicine, with the goal of translating genetic research into treatments that can benefit patients in the UAE and globally. The partnership will leverage insights from the Emirati Genome Programme to support the development of next-generation therapies for inherited diseases, while also expanding research and manufacturing capabilities in Abu Dhabi. Driving the future of precision medicine. Dr Noura Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, said the partnership reflects the emirate's long-term commitment to advancing healthcare innovation. "Abu Dhabi has built a strong foundation in genomics and precision medicine through sustained investments in research and innovation. The next step is translating these insights into therapies that can address some of the most complex diseases affecting communities in our region and globally," she said. Under the agreement, the Department of Health - Abu Dhabi will provide the regulatory and research framework, while M42 will contribute its genomics expertise, healthcare network, and clinical research infrastructure. Mammoth Biosciences will bring its CRISPR-based gene-editing technology to the collaboration. Dr Fahed Al Marzooqi, Chief Executive Officer of Integrated Health Solutions at M42, said the Emirati Genome Programme has generated valuable insights into the health needs of the local population. "Through this collaboration, we are building on that foundation by supporting the development of advanced therapies while strengthening Abu Dhabi's research, clinical, and manufacturing capabilities," he said. Building local expertise and manufacturing capacity. Mammoth Biosciences, co-founded by Nobel Prize-winning scientist Jennifer Doudna, develops gene-editing technologies aimed at treating inherited diseases by correcting genetic mutations rather than merely managing symptoms. The agreement also includes plans to introduce Mammoth's lead clinical candidate, MB-111, into Abu Dhabi's clinical research ecosystem and support advanced gene-therapy trials in the emirate. It also outlines plans to develop advanced therapy manufacturing capabilities, starting with lipid nanoparticle production and later expanding into fully integrated manufacturing facilities. In addition, the partnership will support training programmes designed to build local expertise in CRISPR-based gene-editing technologies and strengthen the UAE's specialised healthcare workforce. The collaboration aligns with Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Cluster, which aims to accelerate healthcare innovation by integrating research, clinical development, manufacturing, and commercialisation within a unified ecosystem. Officials said the agreement represents another milestone in Abu Dhabi's efforts to establish itself as a global hub for life sciences, advanced therapies, and precision medicine.